Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
Subjects must have histologically or cytologically confirmed WHO grade 4 glioma for which disease recurrence/progression after first line therapy is diagnosed by the treating physician.
Subjects must not have received sitagliptin or bevacizumab for this disease.
Age >18 years
Performance status: ECOG performance status 0-2
Prior treatment toxicities not resolved to ≤ Grade 1 according to NCI CTCAE Version 5.0 except for alopecia and neuropathy.
Subjects receiving any other investigational agents.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sitagliptin or bevacizumab.
Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Kailin Yang, MD, PhD
Lead sponsor
University of Iowa
Sponsor institution